160 related articles for article (PubMed ID: 24162837)
61. Radiolabeling, stability studies, and pharmacokinetic evaluation of thulium-170-labeled acyclic and cyclic polyaminopolyphosphonic acids.
Vats K; Das T; Sarma HD; Banerjee S; Pillai MR
Cancer Biother Radiopharm; 2013 Dec; 28(10):737-45. PubMed ID: 23931111
[TBL] [Abstract][Full Text] [Related]
62. Preparation and preliminary biological evaluation of a novel 109Pd labeled porphyrin derivative for possible use in targeted tumor therapy.
Chakraborty S; Das T; Banerjee S; Sarma HD; Venkatesh M
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):16-23. PubMed ID: 17372569
[TBL] [Abstract][Full Text] [Related]
63. Physical optimization of production by deuteron irradiation of high specific activity (177g)Lu suitable for radioimmunotherapy.
Manenti S; Bonardi ML; Gini L; Groppi F
Nucl Med Biol; 2014; 41(5):407-9. PubMed ID: 24666720
[TBL] [Abstract][Full Text] [Related]
64. Development of (177)Lu-phytate Complex for Radiosynovectomy.
Yousefnia H; Jalilian AR; Bahrami-Samani A; Mazidi M; Ghannadi Maragheh M; Abbasi-Davani F
Iran J Basic Med Sci; 2013 May; 16(5):705-9. PubMed ID: 23826493
[TBL] [Abstract][Full Text] [Related]
65. Radiolabeling, quality control, biodistribution, and imaging studies of
Xu Q; Zhang S; Zhao Y; Feng Y; Liu L; Cai L; Zhang W; Huang Z; Wei H; Zhuo L; Chen Y
J Labelled Comp Radiopharm; 2019 Jan; 62(1):43-51. PubMed ID: 30426535
[TBL] [Abstract][Full Text] [Related]
66. 175Yb labeled polyaminophosphonates as potential agents for bone pain palliation.
Mathew B; Chakraborty S; Das T; Sarma HD; Banerjee S; Samuel G; Venkatesh M; Pillai MR
Appl Radiat Isot; 2004 May; 60(5):635-42. PubMed ID: 15082040
[TBL] [Abstract][Full Text] [Related]
67. Practicality of production of ³²P by direct neutron activation for its utilization in bone pain palliation as Na₃[³²P]PO₄.
Vimalnath KV; Shetty P; Chakraborty S; Das T; Chirayil V; Sarma HD; Jagadeesan KC; Joshi PV
Cancer Biother Radiopharm; 2013 Jun; 28(5):423-8. PubMed ID: 23611187
[TBL] [Abstract][Full Text] [Related]
68. Synthesis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors.
Chen J; Linder KE; Cagnolini A; Metcalfe E; Raju N; Tweedle MF; Swenson RE
Appl Radiat Isot; 2008 Apr; 66(4):497-505. PubMed ID: 18178448
[TBL] [Abstract][Full Text] [Related]
69. Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production.
Uusijärvi H; Bernhardt P; Rösch F; Maecke HR; Forssell-Aronsson E
J Nucl Med; 2006 May; 47(5):807-14. PubMed ID: 16644751
[TBL] [Abstract][Full Text] [Related]
70. Investigation of Radiolabeling Efficacy by Enhancement of the Chemical form of no Carrier Added
Vosoughi S; Salek N; Arani SS; Samani AB; Maragheh MG
Curr Radiopharm; 2022; 15(1):56-62. PubMed ID: 33480353
[TBL] [Abstract][Full Text] [Related]
71. Preparation, evaluation, and first clinical use of 177Lu-labeled hydroxyapatite (HA) particles in the treatment of rheumatoid arthritis: utility of cold kits for convenient dose formulation at hospital radiopharmacy.
Chakraborty S; Vimalnath KV; Rajeswari A; Shinto A; Sarma HD; Kamaleshwaran K; Thirumalaisamy P; Dash A
J Labelled Comp Radiopharm; 2014 Jun; 57(7):453-62. PubMed ID: 24966157
[TBL] [Abstract][Full Text] [Related]
72. The low-energy β(-) and electron emitter (161)Tb as an alternative to (177)Lu for targeted radionuclide therapy.
Lehenberger S; Barkhausen C; Cohrs S; Fischer E; Grünberg J; Hohn A; Köster U; Schibli R; Türler A; Zhernosekov K
Nucl Med Biol; 2011 Aug; 38(6):917-24. PubMed ID: 21843788
[TBL] [Abstract][Full Text] [Related]
73. Preliminary Studies of
Zhou L; Chen L; Yang L; Cai L; Liu L; Zhao Y; Feng Y; Liu N; Zhao Y; Xia Y; Wei H; Chen Y
Cancer Biother Radiopharm; 2020 Feb; 35(1):33-40. PubMed ID: 31750727
[No Abstract] [Full Text] [Related]
74. Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer.
Das T; Chakraborty S; Sarma HD; Venkatesh M; Banerjee S
Nucl Med Commun; 2009 May; 30(5):362-7. PubMed ID: 19282794
[TBL] [Abstract][Full Text] [Related]
75. Preparation and preliminary biological evaluation of a 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia.
Das T; Chakraborty S; Banerjee S; Mukherjee A; Samuel G; Sarma HD; Nair CK; Kagiya VT; Venkatesh M
Bioorg Med Chem; 2004 Dec; 12(23):6077-84. PubMed ID: 15519153
[TBL] [Abstract][Full Text] [Related]
76. Studies on the Labeling of Ethylenediaminetetramethylene Phosphonic Acid, Methylene Diphosphonate, Sodium Pyrophosphate and Hydroxyapatite with Lutetium-177 for use in Nuclear Medicine.
Abbasi IA
World J Nucl Med; 2015; 14(2):95-100. PubMed ID: 26097419
[TBL] [Abstract][Full Text] [Related]
77. Rhemium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation.
Ogawa K; Mukai T; Arano Y; Otaka A; Ueda M; Uehara T; Magata Y; Hashimoto K; Saji H
Nucl Med Biol; 2006 May; 33(4):513-20. PubMed ID: 16720243
[TBL] [Abstract][Full Text] [Related]
78.
Kumar C; Sharma R; Das T; Korde A; Sarma H; Banerjee S; Dash A
J Labelled Comp Radiopharm; 2018 Sep; 61(11):837-846. PubMed ID: 29923620
[TBL] [Abstract][Full Text] [Related]
79. Synthetic approaches and bio-distribution studies of [11C]methyl-phenidate.
Patt M; Solbach C; Wüllner U; Blocher A; Stahlschmidt A; Gündisch D; Kovar KA; Machulla HJ
J Pharm Pharm Sci; 2007; 10(2):312s-320s. PubMed ID: 17718934
[TBL] [Abstract][Full Text] [Related]
80. The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.
Örbom A; Eriksson SE; Elgström E; Ohlsson T; Nilsson R; Tennvall J; Strand SE
J Nucl Med; 2013 Aug; 54(8):1404-10. PubMed ID: 23804328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
